Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021

Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021

Abstract Introduction Due to concerns over potential interactions between some hepatitis C direct-acting antivirals (DAAs) and opioids, we describe adverse event (AE) reports of concomitant use of opioids and DAAs. Methods AEs reported (July 28, 2017–December 31, 2021) with the administration of the...

Full description

Bibliographic Details
Main Authors: Anthony Martinez, Tipu Khan, Douglas E. Dylla, John Marcinak, Michelle Collins, Brad Saget, Brian Conway
Format: Article
Language:English
Published: BMC 2023-10-01
Series:Harm Reduction Journal
Subjects:
Addiction
Clinical populations
Hepatitis
Safety
Substance abuse
Online Access:https://doi.org/10.1186/s12954-023-00874-y

Internet

https://doi.org/10.1186/s12954-023-00874-y

Similar Items